Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Plans Additional Clinical Trials Following Successful Tests
Company recently announced significant findings of cardiovascular performance improvements with TurboCBD Lexaria plans additional human clinical trials of CBD Company is now moving forward with clinical studies on oral forms of nicotine delivery following a large investment agreement Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a food bioscience company that developed and commercialized cost-effective drug delivery platform DehydraTECH. This technology enhances the performance of beneficial compounds in ingestible products. Currently, Lexaria has patents pending worldwide for use of the technology in a range of bioactive molecules, including cannabinoids, nicotine, NSAID pain relievers and more. Leveraging this platform, the taste,…